Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50

Capricor Therapeutics Inc (NASDAQ:CAPR) has been given a consensus rating of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.50.

Several research analysts recently commented on the stock. Cantor Fitzgerald raised their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Maxim Group lifted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Capricor Therapeutics in the third quarter worth $458,000. Barclays PLC raised its stake in shares of Capricor Therapeutics by 106.6% during the third quarter. Barclays PLC now owns 36,296 shares of the biotechnology company’s stock valued at $552,000 after purchasing an additional 18,724 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Capricor Therapeutics during the third quarter valued at about $938,000. State Street Corp raised its stake in shares of Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Finally, Sassicaia Capital Advisers LLC bought a new stake in Capricor Therapeutics in the third quarter worth about $192,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $16.51 on Friday. Capricor Therapeutics has a one year low of $2.99 and a one year high of $23.40. The company’s 50 day moving average price is $18.46 and its 200 day moving average price is $9.61. The firm has a market capitalization of $750.71 million, a price-to-earnings ratio of -15.58 and a beta of 3.98.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.